A retrospective cohort study comparing the healthcare resource use and cost between Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for the first line treatment of Follicular Lymphoma
Latest Information Update: 03 Feb 2022
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 03 Feb 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition